Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 8/20 | 0.43 |
| ▸ | KDM5A | P29375 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.41 |
| ▸ | KDM4A | O75164 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4617384 | 0.87 | KDM5B (0.36) | KDM5BKDM5AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5271758 | 0.86 | KDM4E (0.44) | KDM5AKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL7260709 | 0.86 | TSHR (0.49) | KDM4EALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL28588411 | 0.83 | KMT2A (0.39) | KDM4EALDH1A1HPGDLMNANPC1 | |
| SCHEMBL4779978 | 0.81 | GRIN2D (0.43) | KDM4EALDH1A1KDM4CCYP1A2HSD17B10 | |
| SCHEMBL5319556 | 0.80 | CYP3A4 (0.49) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4725858 | 0.79 | HDAC6 (0.42) | KDM4EALDH1A1LMNAKDM4CHSD17B10 | |
| SCHEMBL1297983 | 0.78 | KDM4E (0.54) | KDM4EHPGD | |
| SCHEMBL23294018 | 0.78 | ALDH1A1 (0.42) | KDM5AKDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL7722688 | 0.78 | TNKS2 (0.50) | KDM5BKDM5AKDM4EALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239936-A | Preparation method of azilsartan medoxomil amide derivative | 珠海润都制药股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-105399738-A | Azilsartan medoxomil preparation method | FANG YANYAN | 2016-03-16 | — | — | CN | claimed |
| WO-2008012852-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS | S.I.M.S. S.r.l. - SOCIETÀ ITALIANA MEDICINALI SCANDICCI (IT) | 2008-01-31 | — | — | WO | claimed |
| US-20070093540-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS | DIPHARMA S.P.A. (IT) | 2007-04-26 | — | — | US | claimed |
| EP-1777224-A2 | A process for the preparation of angiotensin II antagonistic compounds | Dipharma S.p.A. (IT) | 2007-04-25 | — | — | EP | claimed |
| CN-118239936-A | Preparation method of azilsartan medoxomil amide derivative | 珠海润都制药股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-3478672-B1 | BIARYLMETHYL HETEROCYCLES | UNIV MONTREAL (CA) | 2024-04-10 | — | — | EP | disclosed |
| CN-113466360-B | Azilsartan 6 related substance detection method | 珠海润都制药股份有限公司 | 2023-03-03 | — | — | CN | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| CN-112745302-A | Benzimidazole compound and medical application thereof | 上海中医药大学附属龙华医院 | 2021-05-04 | — | — | CN | disclosed |
| CN-111699183-A | Method for producing azilsartan A-type crystal | 株式会社德山 | 2020-09-22 | — | — | CN | disclosed |
| CN-107056757-A | A kind of preparation method of Candesartan | 峨眉山宏昇药业股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
| US-20150239854-A1 | DEPROTECTION METHOD FOR TETRAZOLE COMPOUND | API CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
| WO-2011134019-A1 | NOVEL BIPHENYL SARTANS | THE UNIVERSITY OF MELBOURNE (AU) | 2011-11-03 | — | — | WO | disclosed |
| WO-2008012852-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS | S.I.M.S. S.r.l. - SOCIETÀ ITALIANA MEDICINALI SCANDICCI (IT) | 2008-01-31 | — | — | WO | disclosed |
| US-7307096-B2 | Combined agents for treatment of glaucoma | SANKYO COMPANY, LIMITED (JP) | 2007-12-11 | — | — | US | disclosed |
| EP-1778650-A1 | PROCESS FOR PREPARING CANDESARTAN CILEXETIL | Dr. Reddy's Laboratories Ltd. (IN) | 2007-05-02 | — | — | EP | disclosed |
| US-20070093540-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS | DIPHARMA S.P.A. (IT) | 2007-04-26 | — | — | US | disclosed |
| EP-1777224-A2 | A process for the preparation of angiotensin II antagonistic compounds | Dipharma S.p.A. (IT) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006015134-A1 | PROCESS FOR PREPARING CANDESARTAN CILEXETIL | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093540-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS | AGTR2, AGTR1, ACE2 | KDM5B 3950/4885KDM5A 4304/4885KDM4E 4484/4885 |
| US-20150239854-A1 | DEPROTECTION METHOD FOR TETRAZOLE COMPOUND | AGTR2, AGTR1, REN | KDM5B 1149/4885KDM5A 1929/4885KDM4E 3714/4885 |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | KDM5B 3448/4885KDM5A 3951/4885KDM4E 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.